menu ☰
menu ˟

Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes

22 Nov 2016

To evaluate the effectiveness and safety of a sodium–glucose cotransporter-2 (SGLT-2) inhibitor, dapagliflozin, in patients with type 2 diabetes mellitus (T2DM) and background glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy.

Click here to view the full article which appeared in Nutrition, Metabolism & Cardiovascular Diseases